A 57-Year-Old Woman with HR+/HER2- Metastatic Breast Cancer

Expert oncologist Hope Rugo, MD, FASCO, reviews the diagnosis and treatment of a 57-year-old woman with HR+/HER2- metastatic breast cancer (mBC).

Expert perspective on the role of ESR1 mutations in HR+/HER2- mBC and best practices on biomarker testing for patients experiencing disease progression on endocrine therapy.

A comprehensive review of treatment options for patients with HR+/HER2- metastatic breast cancer who experience disease progression on standard-of-care therapies such as combination CDK4/6 and aromatase inhibitors.

Centering discussion on the EMERALD trial, Dr Hope Rugo, reflects on the safety and efficacy of elacestrant in patients with HR+/HER2- mBC.

Dr Hope Rugo shares insight on how she approaches second-line and higher treatment selection in patients with HR+/HER2- metastatic breast cancer who experience disease progression on first-line therapy.

Closing out her discussion on the treatment and management of HR+/HER2- mBC, Hope Rugo, MD, FASCO, highlights unmet needs and future directions in the field.